AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Boosted by Integrated Advisors Network LLC

Integrated Advisors Network LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,513 shares of the company’s stock after purchasing an additional 342 shares during the quarter. Integrated Advisors Network LLC’s holdings in AstraZeneca were worth $439,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. Charles Schwab Investment Management Inc. boosted its stake in AstraZeneca by 237.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,018 shares of the company’s stock valued at $8,331,000 after purchasing an additional 86,610 shares in the last quarter. Glenview Trust co lifted its position in shares of AstraZeneca by 3.8% during the 3rd quarter. Glenview Trust co now owns 4,724 shares of the company’s stock valued at $320,000 after acquiring an additional 174 shares during the last quarter. Rathbones Group PLC acquired a new stake in shares of AstraZeneca during the 3rd quarter valued at $913,000. Clearbridge Investments LLC lifted its position in shares of AstraZeneca by 134.8% during the 3rd quarter. Clearbridge Investments LLC now owns 1,640,856 shares of the company’s stock valued at $111,119,000 after acquiring an additional 941,917 shares during the last quarter. Finally, LPL Financial LLC lifted its position in shares of AstraZeneca by 2.4% during the 3rd quarter. LPL Financial LLC now owns 328,458 shares of the company’s stock valued at $22,243,000 after acquiring an additional 7,582 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $78.42 on Wednesday. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. The firm has a market cap of $243.14 billion, a price-to-earnings ratio of 38.44, a P/E/G ratio of 1.43 and a beta of 0.48. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $80.86. The business has a fifty day simple moving average of $75.90 and a 200 day simple moving average of $69.60.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Thursday, April 25th. The company reported $1.03 EPS for the quarter, topping the consensus estimate of $0.95 by $0.08. The firm had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. As a group, sell-side analysts predict that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AZN. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. The Goldman Sachs Group began coverage on AstraZeneca in a report on Thursday, May 30th. They issued a “buy” rating and a $97.00 target price for the company. BMO Capital Markets increased their target price on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Finally, Argus increased their target price on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.